心血管医疗器械开发商Artivion完成对Endospan的收购-动脉网

Artivion Completes Acquisition of Endospan Ltd.

CISION 等信源发布 2026-05-18 18:58



可切换为仅中文







ATLANTA

亚特兰大

，

May 18, 2026

2026年5月18日

Artivion, Inc. (NYSE:

阿提维恩公司（纽约证券交易所：

AORT

主动脉

), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ('Endospan'), a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS® Aortic Arch System. Artivion utilized its previously drawn $150 million delayed draw term loan to fund the $135 million upfront net purchase price for Endospan.

），一家专注于主动脉疾病的领先心脏和血管外科公司，今天宣布已完成对其长期合作伙伴Endospan有限公司（“Endospan”）的收购，Endospan是主动脉弓疾病腔内修复的先驱，并开发了NEXUS®主动脉弓系统。Artivion利用其先前提取的1.5亿美元延迟提款定期贷款为Endospan支付了1.35亿美元的前期净购买价格。

The transaction also includes potential additional consideration contingent on commercial performance..

该交易还包括取决于商业表现的潜在额外对价。

The U.S. Food and Drug Administration (FDA) approved the premarket approval application (PMA) for the NEXUS branched endovascular stent graft system in April 2026. Artivion has acted as the exclusive distributor of the NEXUS System across EMEA since 2019.

美国食品和药物管理局 (FDA) 于2026年4月批准了NEXUS分支血管内支架移植系统的上市前批准申请 (PMA)。自2019年以来，Artivion一直作为NEXUS系统在欧洲、中东和非洲地区的独家经销商。

'Our acquisition of Endospan and its NEXUS system completes our market-leading, three-pronged aortic arch portfolio. This technology, alongside AMDS and ARCEVO LSA, positions us at the forefront of this segment as the only company globally with a complete portfolio of aortic arch solutions,' said Pat Mackin, Chairman, President, and Chief Executive Officer.

“我们对Endospan及其NEXUS系统的收购完善了我们在市场领先的三管齐下的主动脉弓产品组合。这项技术与AMDS和ARCEVO LSA一起，使我们成为该领域的前沿公司，也是全球唯一一家拥有完整主动脉弓解决方案产品组合的公司，”董事长、总裁兼首席执行官帕特·麦金表示。

'Further, NEXUS is a platform technology, not just a single product. With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time.'.

“此外，NEXUS 是一个平台技术，而不仅仅是一个单一的产品。通过这次收购，我们还增加了一个强大的下一代弓形技术管道，目前这些技术正在开发中，我们预计这将进一步扩大和加强我们在主动脉弓市场的领导地位。”

About Artivion, Inc.

关于Artivion公司

Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues.

总部位于乔治亚州亚特兰大郊区的Artivion, Inc.是一家医疗设备公司，专注于开发解决心脏和血管外科医生在治疗主动脉疾病患者时面临的最困难挑战的简单、优雅的解决方案。Artivion的四大类产品包括：主动脉支架移植物、外科密封剂、On-X机械心脏瓣膜以及可植入的心脏和血管人体组织。

Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, .

Artivion 在全球 100 多个国家销售和推广产品。如需更多关于 Artivion 的信息，请访问我们的网站。

www.Artivion.com

。

About Endospan Ltd.

关于Endospan有限公司

Privately held Endospan, headquartered in Herzliya (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan has received CE-Mark to commercialize in Europe the NEXUS Stent Graft System, the first endovascular off-the-shelf system to treat Aortic Arch Disease which affects a greatly underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch.

总部位于以色列赫兹利亚（特拉维夫）的私人控股公司Endospan是主动脉弓疾病（包括动脉瘤和夹层）腔内修复领域的先驱。Endospan已获得CE标志，可以在欧洲商业化推广NEXUS支架移植系统，这是首个用于治疗主动脉弓疾病的腔内现成系统，针对的是诊断出主动脉弓或其附近存在扩张性病变的一个服务严重不足的患者群体。

While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation.

虽然微创血管内修复术已成为腹主动脉瘤 (AAA) 的标准治疗方法，但患有动脉瘤或夹层的主动脉弓疾病患者却没那么幸运，他们几乎别无选择，只能接受开胸手术，承受其带来的侵入性、风险、漫长的住院时间和恢复期。

For additional information about Endospan, visit their website, .

有关Endospan的更多信息，请访问其网站。

www.endospan.com

。

Contacts:

联系人：

Artivion

阿提维恩

Gilmartin Group LLC

吉尔马丁集团有限责任公司

Lance A. Berry